LAS VEGAS — A VEGF/Ang-2 inhibitor demonstrated faster drying compared with faricimab in patients with diabetic macular edema, according to a study presented at Clinical Trials at the Summit.
Margaret Chang, MD, MS, of Retinal Consultants Medical Group in Sacramento, California, presented results from the JADE proof-of-concept trial, which compared OLN324 (Ollin Biosciences) vs. Vabysmo (faricimab, Genentech) in patients with DME.
{{VIDEO}}
The trial included 83 patients with DME who were either treatment naive or previously treated. Patients were divided into three groups: OLN324 2 mg (27